Friday, October 27, 2006

AstraZeneca - Seroquel: more bad news

AstraZeneca received subpoenas from state regulators in California and Alaska last month seeking information about its marketing of an antipsychotic medication, the drug maker disclosed Thursday.

The UK based company also said it received an informal inquiry from the U.S. Securities and Exchange Commission seeking information about payments made to doctors and government officials in certain countries outside the United States, which the company didn't identify.

In a document posted on its Web site, AstraZeneca said it received a subpoena from the California Attorney General's Office seeking information about the marketing and sale of Seroquel in the state. The subpoena also sought information about the drug's status on the "state's formulary," AstraZeneca said, which could be a reference to state programs covering prescription drugs.

AstraZeneca received a separate subpoena from the Alaska Attorney General's Office last month seeking information about the safety and efficacy of Seroquel, as well as marketing practices for the drug, the company said.


No comments: